nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentazocine—EBP—Azacitidine—Gemcitabine—urinary bladder cancer	0.0177	1	CbGdCrCtD
Pentazocine—EBP—female reproductive system—urinary bladder cancer	0.00698	0.204	CbGeAlD
Pentazocine—OPRK1—prostate gland—urinary bladder cancer	0.00587	0.172	CbGeAlD
Pentazocine—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.00422	0.00445	CcSEcCtD
Pentazocine—Cramp muscle—Etoposide—urinary bladder cancer	0.00422	0.00445	CcSEcCtD
Pentazocine—Dizziness—Mitomycin—urinary bladder cancer	0.00422	0.00445	CcSEcCtD
Pentazocine—Tinnitus—Thiotepa—urinary bladder cancer	0.00421	0.00444	CcSEcCtD
Pentazocine—OPRD1—renal system—urinary bladder cancer	0.00417	0.122	CbGeAlD
Pentazocine—Ulcer—Methotrexate—urinary bladder cancer	0.00409	0.00432	CcSEcCtD
Pentazocine—Sweating—Gemcitabine—urinary bladder cancer	0.00406	0.00428	CcSEcCtD
Pentazocine—Vomiting—Mitomycin—urinary bladder cancer	0.00406	0.00428	CcSEcCtD
Pentazocine—Chills—Thiotepa—urinary bladder cancer	0.00405	0.00427	CcSEcCtD
Pentazocine—Dermatitis—Mitomycin—urinary bladder cancer	0.00402	0.00424	CcSEcCtD
Pentazocine—Headache—Mitomycin—urinary bladder cancer	0.004	0.00422	CcSEcCtD
Pentazocine—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.00395	0.00417	CcSEcCtD
Pentazocine—Sweating increased—Etoposide—urinary bladder cancer	0.00395	0.00416	CcSEcCtD
Pentazocine—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00388	0.0041	CcSEcCtD
Pentazocine—Ulcer—Epirubicin—urinary bladder cancer	0.00383	0.00404	CcSEcCtD
Pentazocine—Nausea—Mitomycin—urinary bladder cancer	0.00379	0.004	CcSEcCtD
Pentazocine—Vision blurred—Thiotepa—urinary bladder cancer	0.00371	0.00391	CcSEcCtD
Pentazocine—Agitation—Thiotepa—urinary bladder cancer	0.00361	0.00381	CcSEcCtD
Pentazocine—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00359	0.00379	CcSEcCtD
Pentazocine—Ulcer—Doxorubicin—urinary bladder cancer	0.00354	0.00374	CcSEcCtD
Pentazocine—SIGMAR1—prostate gland—urinary bladder cancer	0.00345	0.101	CbGeAlD
Pentazocine—Visual impairment—Cisplatin—urinary bladder cancer	0.00341	0.0036	CcSEcCtD
Pentazocine—Chills—Gemcitabine—urinary bladder cancer	0.00341	0.0036	CcSEcCtD
Pentazocine—Hypertension—Thiotepa—urinary bladder cancer	0.00339	0.00358	CcSEcCtD
Pentazocine—Agranulocytosis—Etoposide—urinary bladder cancer	0.00337	0.00356	CcSEcCtD
Pentazocine—Tinnitus—Cisplatin—urinary bladder cancer	0.0033	0.00348	CcSEcCtD
Pentazocine—Flushing—Cisplatin—urinary bladder cancer	0.00329	0.00347	CcSEcCtD
Pentazocine—Confusional state—Thiotepa—urinary bladder cancer	0.00324	0.00341	CcSEcCtD
Pentazocine—OPRK1—female reproductive system—urinary bladder cancer	0.0032	0.0938	CbGeAlD
Pentazocine—Tachycardia—Thiotepa—urinary bladder cancer	0.00313	0.0033	CcSEcCtD
Pentazocine—Erythema multiforme—Etoposide—urinary bladder cancer	0.00307	0.00324	CcSEcCtD
Pentazocine—Vision blurred—Fluorouracil—urinary bladder cancer	0.00307	0.00323	CcSEcCtD
Pentazocine—Anorexia—Thiotepa—urinary bladder cancer	0.00306	0.00323	CcSEcCtD
Pentazocine—Flushing—Etoposide—urinary bladder cancer	0.00301	0.00318	CcSEcCtD
Pentazocine—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.00301	0.00317	CcSEcCtD
Pentazocine—Visual disturbance—Methotrexate—urinary bladder cancer	0.00296	0.00313	CcSEcCtD
Pentazocine—Muscle spasms—Cisplatin—urinary bladder cancer	0.00296	0.00313	CcSEcCtD
Pentazocine—SIGMAR1—seminal vesicle—urinary bladder cancer	0.00292	0.0854	CbGeAlD
Pentazocine—Chills—Etoposide—urinary bladder cancer	0.00291	0.00307	CcSEcCtD
Pentazocine—Vision blurred—Cisplatin—urinary bladder cancer	0.00291	0.00306	CcSEcCtD
Pentazocine—Tremor—Cisplatin—urinary bladder cancer	0.00289	0.00305	CcSEcCtD
Pentazocine—Paraesthesia—Thiotepa—urinary bladder cancer	0.00288	0.00304	CcSEcCtD
Pentazocine—Hypertension—Gemcitabine—urinary bladder cancer	0.00286	0.00301	CcSEcCtD
Pentazocine—Somnolence—Thiotepa—urinary bladder cancer	0.00285	0.00301	CcSEcCtD
Pentazocine—Decreased appetite—Thiotepa—urinary bladder cancer	0.00279	0.00294	CcSEcCtD
Pentazocine—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.00278	0.00294	CcSEcCtD
Pentazocine—Dysgeusia—Etoposide—urinary bladder cancer	0.00277	0.00292	CcSEcCtD
Pentazocine—Constipation—Thiotepa—urinary bladder cancer	0.00274	0.00289	CcSEcCtD
Pentazocine—Muscle spasms—Etoposide—urinary bladder cancer	0.00272	0.00286	CcSEcCtD
Pentazocine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.0027	0.00285	CcSEcCtD
Pentazocine—Irritability—Methotrexate—urinary bladder cancer	0.00268	0.00283	CcSEcCtD
Pentazocine—Confusional state—Fluorouracil—urinary bladder cancer	0.00268	0.00282	CcSEcCtD
Pentazocine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00265	0.0028	CcSEcCtD
Pentazocine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00264	0.00279	CcSEcCtD
Pentazocine—Diplopia—Epirubicin—urinary bladder cancer	0.00263	0.00277	CcSEcCtD
Pentazocine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00261	0.00275	CcSEcCtD
Pentazocine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00259	0.00273	CcSEcCtD
Pentazocine—Anorexia—Gemcitabine—urinary bladder cancer	0.00257	0.00271	CcSEcCtD
Pentazocine—Face oedema—Epirubicin—urinary bladder cancer	0.00254	0.00268	CcSEcCtD
Pentazocine—Vertigo—Etoposide—urinary bladder cancer	0.00254	0.00268	CcSEcCtD
Pentazocine—Anorexia—Fluorouracil—urinary bladder cancer	0.00253	0.00267	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00253	0.00267	CcSEcCtD
Pentazocine—Hypotension—Gemcitabine—urinary bladder cancer	0.00252	0.00266	CcSEcCtD
Pentazocine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00252	0.00265	CcSEcCtD
Pentazocine—Loss of consciousness—Etoposide—urinary bladder cancer	0.00248	0.00262	CcSEcCtD
Pentazocine—Hypotension—Fluorouracil—urinary bladder cancer	0.00248	0.00262	CcSEcCtD
Pentazocine—Tachycardia—Cisplatin—urinary bladder cancer	0.00246	0.00259	CcSEcCtD
Pentazocine—SIGMAR1—smooth muscle tissue—urinary bladder cancer	0.00244	0.0715	CbGeAlD
Pentazocine—Insomnia—Gemcitabine—urinary bladder cancer	0.00244	0.00258	CcSEcCtD
Pentazocine—Hypertension—Etoposide—urinary bladder cancer	0.00244	0.00257	CcSEcCtD
Pentazocine—Diplopia—Doxorubicin—urinary bladder cancer	0.00243	0.00257	CcSEcCtD
Pentazocine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00243	0.00257	CcSEcCtD
Pentazocine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00242	0.00256	CcSEcCtD
Pentazocine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00241	0.00254	CcSEcCtD
Pentazocine—Eosinophilia—Methotrexate—urinary bladder cancer	0.0024	0.00254	CcSEcCtD
Pentazocine—Insomnia—Fluorouracil—urinary bladder cancer	0.0024	0.00253	CcSEcCtD
Pentazocine—Somnolence—Gemcitabine—urinary bladder cancer	0.0024	0.00253	CcSEcCtD
Pentazocine—Anorexia—Cisplatin—urinary bladder cancer	0.0024	0.00253	CcSEcCtD
Pentazocine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00238	0.00251	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00237	0.0025	CcSEcCtD
Pentazocine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00237	0.0025	CcSEcCtD
Pentazocine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00236	0.00249	CcSEcCtD
Pentazocine—Somnolence—Fluorouracil—urinary bladder cancer	0.00236	0.00249	CcSEcCtD
Pentazocine—Hypotension—Cisplatin—urinary bladder cancer	0.00235	0.00248	CcSEcCtD
Pentazocine—Face oedema—Doxorubicin—urinary bladder cancer	0.00235	0.00248	CcSEcCtD
Pentazocine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00235	0.00248	CcSEcCtD
Pentazocine—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00233	0.00246	CcSEcCtD
Pentazocine—Confusional state—Etoposide—urinary bladder cancer	0.00232	0.00245	CcSEcCtD
Pentazocine—SIGMAR1—urethra—urinary bladder cancer	0.00231	0.0676	CbGeAlD
Pentazocine—Constipation—Gemcitabine—urinary bladder cancer	0.00231	0.00243	CcSEcCtD
Pentazocine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00231	0.00243	CcSEcCtD
Pentazocine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00231	0.00243	CcSEcCtD
Pentazocine—Asthenia—Thiotepa—urinary bladder cancer	0.0023	0.00243	CcSEcCtD
Pentazocine—Pruritus—Thiotepa—urinary bladder cancer	0.00227	0.00239	CcSEcCtD
Pentazocine—Paraesthesia—Cisplatin—urinary bladder cancer	0.00226	0.00238	CcSEcCtD
Pentazocine—Tachycardia—Etoposide—urinary bladder cancer	0.00225	0.00237	CcSEcCtD
Pentazocine—Eosinophilia—Epirubicin—urinary bladder cancer	0.00225	0.00237	CcSEcCtD
Pentazocine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00224	0.00237	CcSEcCtD
Pentazocine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00223	0.00235	CcSEcCtD
Pentazocine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00222	0.00235	CcSEcCtD
Pentazocine—Anorexia—Etoposide—urinary bladder cancer	0.0022	0.00232	CcSEcCtD
Pentazocine—Diarrhoea—Thiotepa—urinary bladder cancer	0.0022	0.00232	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00219	0.00231	CcSEcCtD
Pentazocine—Decreased appetite—Cisplatin—urinary bladder cancer	0.00219	0.00231	CcSEcCtD
Pentazocine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00219	0.00231	CcSEcCtD
Pentazocine—Hypotension—Etoposide—urinary bladder cancer	0.00215	0.00227	CcSEcCtD
Pentazocine—Dizziness—Thiotepa—urinary bladder cancer	0.00212	0.00224	CcSEcCtD
Pentazocine—Eosinophilia—Doxorubicin—urinary bladder cancer	0.00208	0.0022	CcSEcCtD
Pentazocine—Sweating—Methotrexate—urinary bladder cancer	0.00208	0.00219	CcSEcCtD
Pentazocine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00207	0.00219	CcSEcCtD
Pentazocine—Paraesthesia—Etoposide—urinary bladder cancer	0.00207	0.00218	CcSEcCtD
Pentazocine—Dyspnoea—Etoposide—urinary bladder cancer	0.00206	0.00217	CcSEcCtD
Pentazocine—Somnolence—Etoposide—urinary bladder cancer	0.00205	0.00216	CcSEcCtD
Pentazocine—Vomiting—Thiotepa—urinary bladder cancer	0.00204	0.00215	CcSEcCtD
Pentazocine—Dermatitis—Thiotepa—urinary bladder cancer	0.00202	0.00213	CcSEcCtD
Pentazocine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.00202	0.00213	CcSEcCtD
Pentazocine—Headache—Thiotepa—urinary bladder cancer	0.00201	0.00212	CcSEcCtD
Pentazocine—Decreased appetite—Etoposide—urinary bladder cancer	0.002	0.00211	CcSEcCtD
Pentazocine—Constipation—Etoposide—urinary bladder cancer	0.00197	0.00208	CcSEcCtD
Pentazocine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00196	0.00206	CcSEcCtD
Pentazocine—Sweating—Epirubicin—urinary bladder cancer	0.00194	0.00205	CcSEcCtD
Pentazocine—Asthenia—Gemcitabine—urinary bladder cancer	0.00194	0.00204	CcSEcCtD
Pentazocine—Pruritus—Gemcitabine—urinary bladder cancer	0.00191	0.00201	CcSEcCtD
Pentazocine—Nausea—Thiotepa—urinary bladder cancer	0.00191	0.00201	CcSEcCtD
Pentazocine—Feeling abnormal—Etoposide—urinary bladder cancer	0.0019	0.002	CcSEcCtD
Pentazocine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00189	0.00199	CcSEcCtD
Pentazocine—Pruritus—Fluorouracil—urinary bladder cancer	0.00188	0.00198	CcSEcCtD
Pentazocine—Visual impairment—Methotrexate—urinary bladder cancer	0.00187	0.00198	CcSEcCtD
Pentazocine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00185	0.00196	CcSEcCtD
Pentazocine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00185	0.00195	CcSEcCtD
Pentazocine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00184	0.00194	CcSEcCtD
Pentazocine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00182	0.00192	CcSEcCtD
Pentazocine—Tinnitus—Methotrexate—urinary bladder cancer	0.00181	0.00191	CcSEcCtD
Pentazocine—Asthenia—Cisplatin—urinary bladder cancer	0.00181	0.0019	CcSEcCtD
Pentazocine—Sweating—Doxorubicin—urinary bladder cancer	0.0018	0.0019	CcSEcCtD
Pentazocine—Dizziness—Fluorouracil—urinary bladder cancer	0.00176	0.00185	CcSEcCtD
Pentazocine—Visual impairment—Epirubicin—urinary bladder cancer	0.00175	0.00185	CcSEcCtD
Pentazocine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00175	0.00185	CcSEcCtD
Pentazocine—Chills—Methotrexate—urinary bladder cancer	0.00174	0.00184	CcSEcCtD
Pentazocine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00172	0.00182	CcSEcCtD
Pentazocine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00172	0.00181	CcSEcCtD
Pentazocine—Vomiting—Gemcitabine—urinary bladder cancer	0.00172	0.00181	CcSEcCtD
Pentazocine—SIGMAR1—vagina—urinary bladder cancer	0.0017	0.0499	CbGeAlD
Pentazocine—Dermatitis—Gemcitabine—urinary bladder cancer	0.0017	0.00179	CcSEcCtD
Pentazocine—Hypersensitivity—Etoposide—urinary bladder cancer	0.0017	0.00179	CcSEcCtD
Pentazocine—Tinnitus—Epirubicin—urinary bladder cancer	0.0017	0.00179	CcSEcCtD
Pentazocine—Headache—Gemcitabine—urinary bladder cancer	0.00169	0.00178	CcSEcCtD
Pentazocine—Flushing—Epirubicin—urinary bladder cancer	0.00169	0.00178	CcSEcCtD
Pentazocine—Vomiting—Fluorouracil—urinary bladder cancer	0.00169	0.00178	CcSEcCtD
Pentazocine—Dermatitis—Fluorouracil—urinary bladder cancer	0.00167	0.00176	CcSEcCtD
Pentazocine—Headache—Fluorouracil—urinary bladder cancer	0.00166	0.00175	CcSEcCtD
Pentazocine—Dysgeusia—Methotrexate—urinary bladder cancer	0.00166	0.00175	CcSEcCtD
Pentazocine—Asthenia—Etoposide—urinary bladder cancer	0.00165	0.00174	CcSEcCtD
Pentazocine—Chills—Epirubicin—urinary bladder cancer	0.00163	0.00172	CcSEcCtD
Pentazocine—Pruritus—Etoposide—urinary bladder cancer	0.00163	0.00172	CcSEcCtD
Pentazocine—Visual impairment—Doxorubicin—urinary bladder cancer	0.00162	0.00171	CcSEcCtD
Pentazocine—Nausea—Gemcitabine—urinary bladder cancer	0.0016	0.00169	CcSEcCtD
Pentazocine—Vomiting—Cisplatin—urinary bladder cancer	0.0016	0.00169	CcSEcCtD
Pentazocine—Vision blurred—Methotrexate—urinary bladder cancer	0.00159	0.00168	CcSEcCtD
Pentazocine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00159	0.00168	CcSEcCtD
Pentazocine—Dermatitis—Cisplatin—urinary bladder cancer	0.00159	0.00167	CcSEcCtD
Pentazocine—Diarrhoea—Etoposide—urinary bladder cancer	0.00158	0.00166	CcSEcCtD
Pentazocine—Nausea—Fluorouracil—urinary bladder cancer	0.00158	0.00166	CcSEcCtD
Pentazocine—Tinnitus—Doxorubicin—urinary bladder cancer	0.00157	0.00165	CcSEcCtD
Pentazocine—Flushing—Doxorubicin—urinary bladder cancer	0.00156	0.00165	CcSEcCtD
Pentazocine—Dysgeusia—Epirubicin—urinary bladder cancer	0.00155	0.00164	CcSEcCtD
Pentazocine—Dizziness—Etoposide—urinary bladder cancer	0.00152	0.00161	CcSEcCtD
Pentazocine—Muscle spasms—Epirubicin—urinary bladder cancer	0.00152	0.00161	CcSEcCtD
Pentazocine—Vertigo—Methotrexate—urinary bladder cancer	0.00152	0.0016	CcSEcCtD
Pentazocine—Chills—Doxorubicin—urinary bladder cancer	0.00151	0.00159	CcSEcCtD
Pentazocine—Nausea—Cisplatin—urinary bladder cancer	0.00149	0.00158	CcSEcCtD
Pentazocine—Vision blurred—Epirubicin—urinary bladder cancer	0.00149	0.00157	CcSEcCtD
Pentazocine—Vomiting—Etoposide—urinary bladder cancer	0.00147	0.00155	CcSEcCtD
Pentazocine—Agitation—Epirubicin—urinary bladder cancer	0.00145	0.00153	CcSEcCtD
Pentazocine—Dermatitis—Etoposide—urinary bladder cancer	0.00145	0.00153	CcSEcCtD
Pentazocine—Headache—Etoposide—urinary bladder cancer	0.00144	0.00152	CcSEcCtD
Pentazocine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00143	0.00151	CcSEcCtD
Pentazocine—Vertigo—Epirubicin—urinary bladder cancer	0.00142	0.0015	CcSEcCtD
Pentazocine—Syncope—Epirubicin—urinary bladder cancer	0.00142	0.0015	CcSEcCtD
Pentazocine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.00141	0.00149	CcSEcCtD
Pentazocine—Confusional state—Methotrexate—urinary bladder cancer	0.00139	0.00147	CcSEcCtD
Pentazocine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00139	0.00147	CcSEcCtD
Pentazocine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00138	0.00146	CcSEcCtD
Pentazocine—Vision blurred—Doxorubicin—urinary bladder cancer	0.00138	0.00146	CcSEcCtD
Pentazocine—Nausea—Etoposide—urinary bladder cancer	0.00137	0.00144	CcSEcCtD
Pentazocine—Hypertension—Epirubicin—urinary bladder cancer	0.00137	0.00144	CcSEcCtD
Pentazocine—Agitation—Doxorubicin—urinary bladder cancer	0.00135	0.00142	CcSEcCtD
Pentazocine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00133	0.00141	CcSEcCtD
Pentazocine—Dry mouth—Epirubicin—urinary bladder cancer	0.00132	0.00139	CcSEcCtD
Pentazocine—Vertigo—Doxorubicin—urinary bladder cancer	0.00132	0.00139	CcSEcCtD
Pentazocine—Anorexia—Methotrexate—urinary bladder cancer	0.00132	0.00139	CcSEcCtD
Pentazocine—Syncope—Doxorubicin—urinary bladder cancer	0.00131	0.00139	CcSEcCtD
Pentazocine—Confusional state—Epirubicin—urinary bladder cancer	0.0013	0.00137	CcSEcCtD
Pentazocine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00129	0.00136	CcSEcCtD
Pentazocine—Hypotension—Methotrexate—urinary bladder cancer	0.00129	0.00136	CcSEcCtD
Pentazocine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00129	0.00136	CcSEcCtD
Pentazocine—Shock—Epirubicin—urinary bladder cancer	0.00127	0.00134	CcSEcCtD
Pentazocine—Hypertension—Doxorubicin—urinary bladder cancer	0.00126	0.00133	CcSEcCtD
Pentazocine—Tachycardia—Epirubicin—urinary bladder cancer	0.00126	0.00133	CcSEcCtD
Pentazocine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00125	0.00132	CcSEcCtD
Pentazocine—Insomnia—Methotrexate—urinary bladder cancer	0.00125	0.00132	CcSEcCtD
Pentazocine—Paraesthesia—Methotrexate—urinary bladder cancer	0.00124	0.00131	CcSEcCtD
Pentazocine—Anorexia—Epirubicin—urinary bladder cancer	0.00123	0.0013	CcSEcCtD
Pentazocine—Dyspnoea—Methotrexate—urinary bladder cancer	0.00123	0.0013	CcSEcCtD
Pentazocine—Somnolence—Methotrexate—urinary bladder cancer	0.00123	0.00129	CcSEcCtD
Pentazocine—Dry mouth—Doxorubicin—urinary bladder cancer	0.00122	0.00129	CcSEcCtD
Pentazocine—Hypotension—Epirubicin—urinary bladder cancer	0.00121	0.00127	CcSEcCtD
Pentazocine—Confusional state—Doxorubicin—urinary bladder cancer	0.00121	0.00127	CcSEcCtD
Pentazocine—Decreased appetite—Methotrexate—urinary bladder cancer	0.0012	0.00127	CcSEcCtD
Pentazocine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.0012	0.00126	CcSEcCtD
Pentazocine—Shock—Doxorubicin—urinary bladder cancer	0.00118	0.00124	CcSEcCtD
Pentazocine—Insomnia—Epirubicin—urinary bladder cancer	0.00117	0.00123	CcSEcCtD
Pentazocine—Tachycardia—Doxorubicin—urinary bladder cancer	0.00117	0.00123	CcSEcCtD
Pentazocine—Paraesthesia—Epirubicin—urinary bladder cancer	0.00116	0.00122	CcSEcCtD
Pentazocine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00116	0.00122	CcSEcCtD
Pentazocine—Dyspnoea—Epirubicin—urinary bladder cancer	0.00115	0.00122	CcSEcCtD
Pentazocine—Somnolence—Epirubicin—urinary bladder cancer	0.00115	0.00121	CcSEcCtD
Pentazocine—Anorexia—Doxorubicin—urinary bladder cancer	0.00114	0.0012	CcSEcCtD
Pentazocine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00114	0.0012	CcSEcCtD
Pentazocine—Decreased appetite—Epirubicin—urinary bladder cancer	0.00112	0.00118	CcSEcCtD
Pentazocine—Hypotension—Doxorubicin—urinary bladder cancer	0.00112	0.00118	CcSEcCtD
Pentazocine—Constipation—Epirubicin—urinary bladder cancer	0.00111	0.00117	CcSEcCtD
Pentazocine—SIGMAR1—lymph node—urinary bladder cancer	0.0011	0.0323	CbGeAlD
Pentazocine—Insomnia—Doxorubicin—urinary bladder cancer	0.00108	0.00114	CcSEcCtD
Pentazocine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00107	0.00113	CcSEcCtD
Pentazocine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00107	0.00112	CcSEcCtD
Pentazocine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00106	0.00112	CcSEcCtD
Pentazocine—Somnolence—Doxorubicin—urinary bladder cancer	0.00106	0.00112	CcSEcCtD
Pentazocine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00104	0.0011	CcSEcCtD
Pentazocine—Constipation—Doxorubicin—urinary bladder cancer	0.00102	0.00108	CcSEcCtD
Pentazocine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00102	0.00107	CcSEcCtD
Pentazocine—Asthenia—Methotrexate—urinary bladder cancer	0.000991	0.00104	CcSEcCtD
Pentazocine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000985	0.00104	CcSEcCtD
Pentazocine—Pruritus—Methotrexate—urinary bladder cancer	0.000977	0.00103	CcSEcCtD
Pentazocine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000952	0.001	CcSEcCtD
Pentazocine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000945	0.000996	CcSEcCtD
Pentazocine—Asthenia—Epirubicin—urinary bladder cancer	0.000927	0.000978	CcSEcCtD
Pentazocine—Pruritus—Epirubicin—urinary bladder cancer	0.000914	0.000964	CcSEcCtD
Pentazocine—Dizziness—Methotrexate—urinary bladder cancer	0.000913	0.000963	CcSEcCtD
Pentazocine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000884	0.000932	CcSEcCtD
Pentazocine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000881	0.000929	CcSEcCtD
Pentazocine—Vomiting—Methotrexate—urinary bladder cancer	0.000878	0.000926	CcSEcCtD
Pentazocine—Dermatitis—Methotrexate—urinary bladder cancer	0.00087	0.000917	CcSEcCtD
Pentazocine—Headache—Methotrexate—urinary bladder cancer	0.000865	0.000912	CcSEcCtD
Pentazocine—Asthenia—Doxorubicin—urinary bladder cancer	0.000858	0.000905	CcSEcCtD
Pentazocine—Dizziness—Epirubicin—urinary bladder cancer	0.000854	0.000901	CcSEcCtD
Pentazocine—Pruritus—Doxorubicin—urinary bladder cancer	0.000846	0.000892	CcSEcCtD
Pentazocine—Vomiting—Epirubicin—urinary bladder cancer	0.000822	0.000867	CcSEcCtD
Pentazocine—Nausea—Methotrexate—urinary bladder cancer	0.00082	0.000865	CcSEcCtD
Pentazocine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000818	0.000863	CcSEcCtD
Pentazocine—Dermatitis—Epirubicin—urinary bladder cancer	0.000814	0.000858	CcSEcCtD
Pentazocine—Headache—Epirubicin—urinary bladder cancer	0.00081	0.000854	CcSEcCtD
Pentazocine—Dizziness—Doxorubicin—urinary bladder cancer	0.000791	0.000834	CcSEcCtD
Pentazocine—Nausea—Epirubicin—urinary bladder cancer	0.000768	0.00081	CcSEcCtD
Pentazocine—Vomiting—Doxorubicin—urinary bladder cancer	0.00076	0.000802	CcSEcCtD
Pentazocine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000753	0.000794	CcSEcCtD
Pentazocine—Headache—Doxorubicin—urinary bladder cancer	0.000749	0.00079	CcSEcCtD
Pentazocine—Nausea—Doxorubicin—urinary bladder cancer	0.00071	0.000749	CcSEcCtD
